Zepbound Shortage 2026: Current Availability Map

Introduction

Zepbound® (tirzepatide) came off the FDA shortage list in December 2024, and Eli Lilly has spent 2025 and 2026 trying to keep it off. The company’s $25 billion manufacturing buildout, including the new Indianapolis plant and the North Carolina expansion, is the largest pharmaceutical capacity investment in U.S. history. It’s not enough.

Patients in 2026 still hit periodic gaps at specific doses, especially the 12.5 mg and 15 mg maintenance strengths. This piece maps what’s available, where, and how to plan around the soft spots.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Is Zepbound Still Hard to Find in 2026?

Less than it was in 2023 to 2024, but not consistently easy. Eli Lilly added significant U.S. fill-finish capacity through 2025, and the 2.5 mg starter and 5 mg dose are stocked at most major pharmacies. The 12.5 mg and 15 mg strengths, which is where most patients land for maintenance after titration, are the chokepoint.

Quick Answer: Zepbound was declared resolved on the FDA shortage list in December 2024

A Lilly investor presentation in early 2026 reported U.S. Zepbound dispensing volume at roughly 3.8 million pens per month, up from 800,000 in mid-2023. The FDA’s Drug Shortage Database has not relisted Zepbound, but localized pharmacy gaps continue. The Texas and Florida markets see the longest delays per IQVIA dispensing data, likely because of population density and high obesity prevalence.

The introduction of single-dose vials in late 2024 added another channel. Vials cost less than the KwikPen presentation and ship from LillyDirect Self-Pay at $349 per month for the 2.5 mg vial and $499 for higher strengths.

Which Zepbound Strengths Are in Stock Right Now?

The 2.5 mg starter dose is widely available everywhere in 2026. The 5 mg and 7.5 mg titration doses generally fill within 1 to 3 days at chain pharmacies. The 10 mg dose sees occasional gaps, usually 5 to 7 days. The 12.5 mg and 15 mg strengths are where patients lose time.

Vials are more consistently available than KwikPens for the higher doses because Lilly’s vial filling capacity expanded faster than autoinjector capacity. If your prescriber is willing to write for vials with manual injection (the kit comes with syringes and instructions), supply chances improve.

The Zepbound Stock Locator on zepbound.lilly.com shows pharmacy-level availability and refreshes every few hours. It’s accurate enough to filter out clearly empty stores. Call the pharmacy directly before driving over.

Why Does the 12.5 Mg Dose Keep Running Out?

Two reasons. First, it’s the dose most patients titrate to before deciding whether to stay or push to 15 mg, so the volume is high. Second, the maintenance doses share fill-finish lines with the diabetes brand Mounjaro® at the same strengths, and Mounjaro’s diabetes indication competes for the same physical capacity.

SURMOUNT-1 demonstrated the 10 mg dose at 15.0% mean weight loss and 15 mg at 20.9% at 72 weeks, so prescribers commonly push patients toward the higher dose for outcomes. That demand pattern stresses the upper end of the supply chain.

Lilly’s Mount Vernon, Indiana plant began commercial production of injectable tirzepatide in late 2025 and should ease the maintenance-dose squeeze through 2026, but full ramp-up takes another two to three quarters.

What Is LillyDirect Self-Pay?

LillyDirect Self-Pay is Eli Lilly’s direct-to-consumer cash channel for Zepbound vials. As of 2026, pricing is $349 per month for 2.5 mg vials, $499 per month for 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg vials. Pens are not sold through Self-Pay; you have to use a traditional pharmacy for those.

The program ships from Lilly’s contracted specialty pharmacy and requires a valid U.S. prescription. There’s no insurance involvement, which means no prior authorization delay. The trade-off is that money paid through Self-Pay doesn’t count toward most insurance deductibles or out-of-pocket maximums.

For patients whose insurance refuses Zepbound or who don’t have insurance, this is the cheapest legitimate U.S. channel for tirzepatide in 2026.

Can I Still Get Compounded Tirzepatide?

Yes, under narrower conditions than in 2024. The FDA declared tirzepatide resolved on the shortage list in December 2024, ending the 503B mass-compounding exception. State-licensed 503A pharmacies can still compound tirzepatide on a patient-specific basis when the prescriber documents a clinical reason commercial product won’t work.

Acceptable reasons include allergies to inactive ingredients in commercial vials or pens, the need for a non-standard dose strength, or combination products. The bar is real and pharmacies that ignore it face state board action. Several large compounders shut down semaglutide and tirzepatide programs in 2025 after FDA enforcement.

TrimRx partners with licensed pharmacies that operate within current FDA guidance. The free assessment quiz documents the clinical case for compounded therapy when it applies.

Key Takeaway: LillyDirect Self-Pay offers all approved Zepbound strengths at $349 to $499 per month for vials

How Do I Find Zepbound Near Me?

Start with the Lilly locator. It pulls inventory data from major wholesalers and refreshes faster than the Wegovy® equivalent. Independent pharmacies often have better access to KwikPen inventory than chains because they don’t compete for the same corporate allocation.

If you live in a metro area, call a pharmacy that does specialty prescriptions, the kind that handles injectables and biologics. Those pharmacies move Zepbound volume and prioritize regular patients.

Mail-order through your insurance plan (Express Scripts, OptumRx, CVS Caremark Mail) is the most reliable channel for maintenance doses. Plans negotiate guaranteed allocations from wholesalers that don’t apply to retail pharmacies.

Should I Switch to Wegovy If Zepbound Isn’t Available?

It depends on dose. If you’re on 5 mg or 7.5 mg Zepbound, switching to Wegovy 1.0 mg or 1.7 mg is a reasonable bridge with prescriber approval. If you’re on 12.5 mg or 15 mg Zepbound, no Wegovy dose matches the weight-loss outcomes you’re getting from tirzepatide. SURMOUNT-1 at 15 mg averaged 20.9%; STEP 1 at 2.4 mg semaglutide averaged 14.9%.

Switching requires a new prescription and usually a new prior authorization. Restart at the lowest dose. Even though both drugs are GLP-1 agonists, the receptor activity differs (tirzepatide hits both GIP and GLP-1), and your gut needs a fresh titration.

Don’t switch without your prescriber. Self-switching between brands or strengths is the fastest way to lose weeks to gastrointestinal side effects.

What Is Eli Lilly’s Plan to Prevent Future Zepbound Shortages?

Lilly committed $25 billion in capital expenditures through 2026 for U.S. manufacturing. The Lebanon, Indiana site is scaled for injectable peptide production at unprecedented volume. The Concord, North Carolina site, completed in early 2025, focuses on fill-finish for autoinjectors. Lilly’s CEO David Ricks has publicly stated the company is building capacity to support 100 million U.S. patients on tirzepatide.

The bottleneck for the rest of 2026 is autoinjector device manufacturing, not the drug substance itself. Pen components come from a small number of global suppliers, and Lilly is in-sourcing more of that supply chain.

Vials are easier to scale than pens, which is why Self-Pay vials are the most reliable Zepbound channel right now.

What If My Prior Authorization Gets Approved but the Pharmacy Can’t Fill It?

Call your insurance plan and ask about a “mail-order override” or a “specialty pharmacy transfer.” Plans can move a prescription from retail to mail-order or to a specialty pharmacy that has the drug in stock without restarting your PA.

If that fails, ask your prescriber to send the prescription to a different pharmacy. The PA approval is tied to you, not the pharmacy, so transferring the script is allowed under most plans.

Document every refused fill. Insurance plans sometimes claim “the drug was available” later, and dated refusal notes from the pharmacy are evidence.

Bottom line: SURMOUNT-OSA led to FDA approval for obstructive sleep apnea in December 2024, broadening the eligible patient pool

FAQ

Is Mounjaro the Same as Zepbound?

Yes, same molecule (tirzepatide). Mounjaro is the diabetes brand, Zepbound is the obesity brand. Same manufacturer, same factories, different labels and indications. Mounjaro is not approved for off-label weight-loss use under most insurance plans.

How Long Has Zepbound Been Off the Shortage List?

Since December 19, 2024. The FDA Drug Shortage Database has not relisted it through May 2026, though pharmacy-level supply remains uneven for specific strengths.

Does the Lilly Stock Locator Show Vial vs Pen Availability?

Yes, separately. Vials and pens have different supply chains and the locator differentiates. If pens are out, check vials at the same pharmacy.

Can I Use a Manufacturer Coupon with LillyDirect Self-Pay?

No. Self-Pay is cash only and doesn’t stack with manufacturer savings cards. Savings cards are designed for insured patients with high copays, not for cash pay.

What Strengths Does LillyDirect Ship?

2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg vials. KwikPens are not sold through Self-Pay.

Will Eli Lilly Raise Zepbound Prices in 2026?

Lilly held Self-Pay pricing steady through Q1 2026. Wholesale acquisition cost for retail pharmacies has not changed since mid-2024. There’s no announced price increase, but contract negotiations with PBMs could shift insurance pricing.

Is TrimRx an Alternative to Zepbound?

TrimRx offers compounded tirzepatide through partnered licensed pharmacies when the clinical case supports it. We aren’t a substitute for brand Zepbound when commercial product works for you. The free assessment quiz reviews your situation.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.